In patients with atrial fibrillation who were unable to receive warfarin for any reason, the use of apixaban reduced the risk of stroke and systemic embolism when compared to aspirin. Study Rundown: Atrial fibrillation is a common arrhythmia that increases the risk of stroke and. AVERROES has shown that the new oral anti-Xa inhibitor apixaban is superior to aspirin in terms of efficacy, with surprisingly similar safety. AVERROES. Apixaban Versus ASA. To Reduce the Risk Of Stroke. Coordinated by Population Health Research institute. Hamilton, Ontario, Canada. Sponsors.
|Published (Last):||13 February 2016|
|PDF File Size:||6.17 Mb|
|ePub File Size:||19.44 Mb|
|Price:||Free* [*Free Regsitration Required]|
There were 11 intracranial bleeds on apixaban and 13 on aspirin apixaban 1.
There were 44 1. Notes to editor Correspondence: Apixanan is a novel oral anticoagulant that inhibits factor Xa.
VKA therapy not recommended by the physician; Aerroes role in prevention of stroke in patients unsuitable for VKA therapy, but maintained on aspirin therapy, was unknown. Don’t miss out Read your latest personalised notifications Ok, got it. Patients were eligible if they were 50 years of age or older and if they had atrial fibrillation that had been documented in the 6 months prior to enrollment or by lead electrocardiography on the day of screening.
Effect of clopidogrel added to aspirin in avrrroes with atrial fibrillation. One may question each of these choices: In patients with atrial fibrillation thought to be unsuitable candidates for anticoagulation with a vitamin K antagonist, apixaban signficantly reduced the risk of stroke and systemic embolism without increasing the risk of major bleeding or intracranial hemorrhage when compared to aspirin.
To get the best experience using our website we recommend that you upgrade to a newer version. N Engl J Med ; Risks and benefits of oral anticoagulation compared with clopidogrel plus aspirin in patients with atrial fibrillation according to stroke risk: Read your latest personalised notifications Sign in No account yet? Avetroes on the indirect comparison with ACTIVE A, one averroex conclude that apixaban is, at the time of writing, the best alternative to aspirin ever found in patients deemed unsuitable for VKAs.
With a mean follow-up of 1. In such patients, aspirin plus clopidogrel reduced the rate of major vascular events, in particular stroke, vs.
The New England Journal of Medicine. There were 51 primary outcome events in those randomised to apixaban 1. Thus, a clear superiority of apixaban over aspirin was shown in terms of efficacy, with comparable safety. Adverse event not related to bleeding during VKA therapy; 3.
The AVERROES Trial – Clinical Implications
In April the Data averrles Safety Monitoring Board recommended early study termination because of clear benefit in favor of apixaban. Apixaban in Patients with Atrial Fibrillation. The median duration of follow-up was 1. Concurrent medications that could alter activity of VKAs; 8. Strengths Strong points and important messages of the study are: Hospitalized patients with atrial fibrillation and a high risk of stroke are not being provided with adequate anticoagulation.
Apixban will here briefly discuss the clinical implications of the trial. All these reasons can be grouped in three broad categories: Presented as apixaban vs. Also, how does apixaban compare to aspirin rates of major bleeding? It has multiple theoretical benefits over VKA therapy including less intensive monitoring and fewer drug interactions.
Assessment that patient would be unable or unlikely to adhere to restrictions on factors such as alcohol and diet; Expected difficulty in contacting patient for urgent change in dose of VKAs; 6. In addition, patients could not be receiving VKA therapy, either because it had been demonstrated unsuitable in their case or because it was expected to be unsuitable.
This page was last modified on 3 Decemberat Sign in to My ESC. AVERROES on the other hand has shown that the new oral anti-Xa inhibitor apixaban is superior to aspirin in terms of efficacy, with surprisingly similar apixavan.
AVERROES – Wiki Journal Club
Connolly SJ, et al. This proportion was similar for both academic and community hospitals. ESC sub specialties communities.
Dual therapy decreased rates of major vascular events at cost of increased major bleeding. Eur Heart J ; Mortality rates were 3.
Retrieved from ” http: To reduce the burden of cardiovascular disease. Apixaban avsrroes, at the time of writing, the best alternative to aspirin in patients deemed unsuitable for vitamin K antagonists. Navigation menu Personal tools Create account Log in.
The AVERROES Trial – Clinical Implications
Analyses are to time of first event. A serious bleeding event during VKA therapy; 4. J Am Coll Cardiol ; The reasons that VKA therapy was unsuitable for the patient had to be documented in the study case report forms. The trial was terminated early given a treatment benefit with apixaban.